



Universiteit  
Leiden  
The Netherlands

## **Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy**

Kumpel, B.M.; Saldova, R.; Koeleman, C.A.M.; Abrahams, J.L.; Ederveen, A.H.; Armour, K.L.; ... ; Wuhrer, M.

### **Citation**

Kumpel, B. M., Saldova, R., Koeleman, C. A. M., Abrahams, J. L., Ederveen, A. H., Armour, K. L., ... Wuhrer, M. (2020). Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy. *Scientific Reports*, 10(1). doi:10.1038/s41598-019-57393-9

Version: Publisher's Version  
License: [Creative Commons CC BY 4.0 license](#)  
Downloaded from: <https://hdl.handle.net/1887/3182086>

**Note:** To cite this publication please use the final published version (if applicable).

OPEN

# Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy

Belinda M. Kumpel<sup>1\*</sup>, Radka Saldova<sup>2</sup>, Carolien A. M. Koeleman<sup>3</sup>, Jodie L. Abrahams<sup>2</sup>, Agnes Hipgrave Ederveen<sup>3</sup>, Kathryn L. Armour<sup>4</sup>, Natalia I. Olovnikova<sup>5</sup>, Gestur Vidarsson<sup>6\*</sup>, Rick Kapur<sup>6</sup>, Pauline M. Rudd<sup>2</sup> & Manfred Wuhrer<sup>3</sup>


Anti-D immunoglobulin (Anti-D Ig) prophylaxis prevents haemolytic disease of the fetus and newborn. Monoclonal IgG anti-Ds (mAb-Ds) would enable unlimited supplies but have differed in efficacy in Fc $\gamma$ R1IIa-mediated ADCC assays and clinical trials. Structural variations of the oligosaccharide chains of mAb-Ds are hypothesised to be responsible. Quantitative data on 12 Fc-glycosylation features of 23 mAb-Ds (12 clones, 5 produced from multiple cell lines) and one blood donor-derived anti-D Ig were obtained by HPLC and mass spectrometry using 3 methods. Glycosylation of mAb-Ds from human B-lymphoblastoid cell lines (B) was similar to anti-D Ig although fucosylation varied, affecting ADCC activity. *In vivo*, two B mAb-Ds with 77–81% fucosylation cleared red cells and prevented D-immunisation but less effectively than anti-D Ig. High fucosylation (>89%) of mouse-human heterohybridoma (HH) and Chinese hamster ovary (CHO) mAb-Ds blocked ADCC and clearance. Rat YB2/0 mAb-Ds with <50% fucosylation mediated more efficient ADCC and clearance than anti-D Ig. Galactosylation of B mAb-Ds was 57–83% but 15–58% for rodent mAb-Ds. HH mAb-Ds had non-human sugars. These data reveal high galactosylation like anti-D Ig (>60%) together with lower fucosylation (<60%) as safe features of mAb-Ds for mediating rapid red cell clearance at low doses, to enable effective, inexpensive prophylaxis.

Anti-D immunoglobulin (anti-D Ig, RhIG) is a very safe and effective prophylactic therapy to prevent haemolytic disease of the fetus and newborn (HDFN). After its introduction 50 years ago, deaths are now rare, approximately 0.02 per thousand births, a reduction of about 98% since 1950 when mortality from HDFN was about 10% of perinatal deaths<sup>1</sup>.

However, in low- or middle-income countries HDFN still affects thousands of babies annually<sup>2</sup>. Worldwide estimates for 2010 were 141,000 fetal and neonatal deaths and 27,000 cases of kernicterus caused by bilirubin toxicity leading to a high risk of lifelong neurological dysfunction<sup>3</sup>. Many countries have insufficient, sporadic or no anti-D prophylaxis due to its unavailability, high cost<sup>4,5</sup> or insufficient public healthcare organisation or resources<sup>2</sup>.

Anti-D Ig preparations consist of IgG fractionated from pooled plasma of hyperimmunised D-negative donors. These IgG preparations have multiple anti-D specificities and affinities. Relatively low doses of this poly-clonal anti-D (100<sup>6</sup>–300<sup>4</sup>  $\mu$ g anti-D) are administered antenatally and/or postnatally to susceptible women,

<sup>1</sup>Bristol Institute for Transfusion Sciences, International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK. <sup>2</sup>NIBRT Glycoscience Group, National Institute for Bioprocessing Research and Training, Dublin, Ireland. <sup>3</sup>Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands. <sup>4</sup>Department of Pathology, University of Cambridge, Cambridge, UK. <sup>5</sup>National Research Center for Hematology, Moscow, Russia. <sup>6</sup>Sanquin Research and Landsteiner Laboratory, Department for Experimental Immunohematology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. \*email: [bm.kumpel@btinternet.com](mailto:bm.kumpel@btinternet.com); [G.Vidarsson@sanquin.nl](mailto:G.Vidarsson@sanquin.nl)



**Figure 1.** Glycosylation of anti-D IgG-Fc. **(a)** Cartoon of the branched oligosaccharide chain covalently attached to Asn297 of each Fc in the C $\gamma$ 2 domain of IgG. The sugar linkages are shown. Dotted lines indicate the structures that may or may not be present on different glycans. **(b)** Summary of glycosylation of anti-Ds. Bar chart showing the average glycosylation of IgG1 mAb-Ds produced from human B, mouse HH + NS0, hamster CHO and rat YB2/0 cell lines, compared to Rhophylac anti-D. The percentage of glycans with fucose, galactose, sialic acid and bisecting GlcNAc of the total samples of each cell line group is illustrated.

which are D-negative with a D-positive fetus or baby. Fetal blood may leak into maternal blood by fetomaternal haemorrhage (FMH) through the placenta, occasionally during pregnancy but more often after parturition<sup>7,8</sup> with fetal bleeds then usually of greater volume but rarely exceeding 5 mL. FMH is the cause of maternal alloimmunisation<sup>9</sup>. Unique immunologic changes in pregnant and postpartum women induced by placental syncytiotrophoblast microparticles<sup>10,11</sup> and pregnancy hormones<sup>12</sup> ensure they make strong protective antibody responses to foreign antigens which include, unfortunately, responses to allogeneic blood cells<sup>13</sup>. Prophylactic anti-D accelerates the clearance of fetal D-positive red blood cells (RBC) from the maternal circulation<sup>14</sup>, preventing D-immunisation which may otherwise result in HDFN. Fetal RBC with bound anti-D are removed by the spleen<sup>15</sup> via macrophage IgG Fc receptor (Fc $\gamma$ R)IIIa recognition of cell-bound anti-D<sup>16,17</sup> which triggers phago-cytosis and non-inflammatory intracellular destruction<sup>18</sup>. Consequently, Fc $\gamma$ RIIIa-mediated antibody-dependent cellular-cytotoxicity (ADCC) assays are a good predictor of red cell clearance by IgG anti-D<sup>19</sup>.

Anti-D monoclonal antibodies (mAb-Ds) would be safe, inexpensive, standardised products potentially capable of replacing anti-D Ig. Several groups have made mAb-Ds and tested them in relevant biological assays *in vitro* and in human studies of RBC clearance and prevention of D-immunisation. Surprisingly, mAb-Ds have shown great variability in these studies but none have yet had equivalent activity to anti-D Ig<sup>19</sup>. It was hypothesised that this may be due to differences in their glycosylation<sup>19,20</sup>, i.e. the composition and linkage of sugars in the oligosaccharide chains attached to the Fc portion of IgG<sup>21</sup>. Human IgG has a highly conserved branched glycan chain covalently attached to Asn297 of each C $\gamma$ 2 domain (Fig. 1a). This glycan contains variable amounts of fucose, galactose, sialic acid, and bisecting N-acetylglucosamine (GlcNAc). Remarkably, we have found that alloimmune IgG1 responses against platelets and RBC antigens, including anti-D, are characterised by low fucosylation and increased galactosylation in most sera<sup>22–24</sup> as well as in the anti-D component of anti-D Ig preparations<sup>25</sup>.

For this study, extensive glycosylation analyses of an anti-D Ig preparation and 23 mAb-Ds produced from cell lines of four species (human, mouse, hamster and rat) were performed independently by two research groups. The mAb-Ds comprised 12 unique clones; 5 of these clones produced anti-D from 2–4 cell lines. Fourteen of these mAb-Ds had been previously tested in 10 clinical studies. Retrospective data analysis of clearance of D-positive RBC by all 14 mAb-Ds and of prevention of D-immunisation by 6 of them is presented here. Glycosylation of IgG1 and IgG3 anti-Ds was determined by high-performance liquid chromatography (HPLC) analysis of fluorescently labelled N-glycans, before and after exoglycosidase digestion. In a second approach, N-glycans from total IgG1 anti-D were analysed by mass spectrometry (MS) after ethyl esterification of sialic acids. In a third approach, MS was also used to analyse IgG1 anti-D Fc-glycopeptides. ADCC assays were performed and glycan structural data were linked to ADCC activity. The data imply that cell line-dependent variations in glycosylation between mAb-Ds had a major influence on biological activity.

Antibody	Cell line	IgG sub- class	% Lysis in ADCC at 2500 ng/mL	% Fucosylation			% Bisecting GlcNAc			% $\alpha$ -Galactose	
				Flu	Eth	GP	Flu	Eth	GP	Flu	Eth
IVIG		1>2>3>4		86.8	95.7	91.6	15.6	18.4	14.2	0.0	0.0
Rhophylac		1	88.2	79.8	82.1	78.0	11.0	12.0	13.2	0.0	0.0
BRAD3lab	B	3	6.5	87.7			65.6			0.0	
BRAD3clin	B	3		77.0			62.0			0.0	
mBRAD3	B	3	25.7	78.9			63.9			0.0	
BRAD5lab	B	1	95.9	67.8	68.9	63.9	48.8	53.9	53.9	0.0	1.1
BRAD5clin	B	1		81.2			65.8			0.0	
mBRAD5	B	1	55.1	87.3	94.0	87.2	35.5	46.8	42.9	0.0	2.3
G7	B	1	10.9	92.5	98.9	94.9	13.3	12.8	15.0	0.0	0.0
G12	B	1	8.8	91.6	99.5	93.9	27.0	34.2	34.8	0.0	0.0
G108	B	1		90.2			86.8			23.2	0.5
AB5	B	1		96.6			96.3			58.7	1.5
JAC10	B	1		98.5			95.3			25.2	2.3
Fog1	NS0	1	5.4	100.0	99.2	92.3	2.3	1.1	4.5	4.4	5.3
Fog1	HH	1	8.4	83.6	100.0	95.9	0.0	0.0	2.5	1.0	0.0
G7	HH	1	47.8	86.0	92.4	90.2	2.5	2.4	3.6	3.5	3.5
G12	HH	1	28.5	96.8	93.0	90.5	2.6	2.3	3.6	0.6	0.4
AD1	HH	1			97.9	96.6		0.4	1.5		3.2
MonoRho	CHO	1	28.0	92.3		92.7	0.0		2.5	0.0	
rBRAD3	CHO	3	17.3	73.6			0.0			0.0	
rBRAD5	CHO	1	32.0	90.9			0.0			0.0	
Fog1	YB2/0	1	107.3	17.5	24.2	27.2	0.0	1.0	2.7	0.0	0.0
G12	YB2/0	1	111.1	20.3	23.0	32.9	7.7	9.4	12.2	0.0	0.0
R297	YB2/0	1			31.6	35.4		0.0	4.5		0.0
Fog1 $\Delta$ nab	YB2/0	1 null				45.6			1.5		

**Table 1.** Analysis of total fucosylation, bisecting N-acetylglucosamine and alpha-galactose of Fc-glycans from IVIG, Rhophylac anti-D and mAb-Ds. Glycosylation analysis methods used were Flu (NP-HPLC analysis of fluorescently labelled, released N-glycans), Eth (analysis of released N-glycans by MALDI-TOF-MS after ethyl esterification) and GP (analysis of IgG Fc-glycopeptides by LC-MS).

## Results

**Glycosylation varied markedly among the anti-Ds.** Results from the three analytical methods determining 12 glycosylation features were similar (Tables 1–3) and concurred with earlier data from small-scale studies (Supplementary Table S1). Glycosylation of intravenous immunoglobulin (IVIG) was similar to other products<sup>26</sup> and that of the IgG anti-D purified from Rhophylac 300 anti-D Ig (Rhophylac) agreed with an earlier report<sup>25</sup>. Glycosylation profiles of the mAb-Ds depended on the producer cell lines. The data is summarised in Fig. 1b.

**Fucosylation.** Fucosylation was high in IVIG (91%), Rhophylac (80%), and mAb-Ds from most human B lymphoblastoid cell lines (B) (67–95%), mouse NS0 and heterohybridoma (HH) cell lines (90–97%) as well as Chinese hamster ovary (CHO) cell lines (74–93%). In contrast, mAb-Ds produced from rat YB2/0 cell lines had much lower fucosylation (23–46%) (Table 1).

**Galactosylation.** The number of galactose residues on the branched oligosaccharide varied greatly. Galactosylation of Rhophylac (84%), most B mAb-Ds (mean 71%) and IVIG (61%) was markedly higher than for rodent cell mAb-Ds (mean 35%). The percentages of G0 (agalactosyl IgG), G1 (monogalactosyl IgG) and G2 (digalactosyl IgG) were calculated for each method. Mean G2 values were over 3 times higher for human (72% Rhophylac, mean 52% B mAb-Ds) than for rodent cell (mean 16%) anti-Ds. G1 values for Rhophylac were slightly lower than for IVIG and most mAb-Ds. Strikingly, nearly half the Fc-glycans of rodent cell mAb-Ds had no galactose (mean 43% G0), contrasting greatly with very low levels of G0 in Rhophylac (3.2%) and IgG1 B mAb-Ds (mean 4.5%) (Table 2).

**Sialylation.** Sialic acid is linked to galactose on IgG Fc oligosaccharides. Sialylation was approximately one third that of galactosylation for IVIG and Rhophylac and was relatively higher for B and HH mAb-Ds but lower for NS0, CHO and YB2/0 mAb-Ds (half had <10% sialylation) (Fig. 1b). IVIG, Rhophylac, B mAb-Ds and two YB2/0 mAb-Ds expressed only N-acetylneuraminic acid (NeuAc) while NS0 and HH cell mAb-Ds had only N-glycolylneuraminic acid (NeuGc) and G12-YB2/0 had both types of sialic acids. The linkage of sialic acid to galactose was predominantly  $\alpha$ 2,6 in IVIG, Rhophylac, B, NS0, HH and YB2/0 mAb-Ds but only  $\alpha$ 2,3 was detected in CHO mAb-Ds (Table 3).

**Bisection.** Compared to Rhophylac and other prophylactic anti-Ds<sup>25</sup>, levels of bisecting N-acetylglucosamine (GlcNAc) were much higher for all B mAb-Ds but lower for all rodent cell mAb-Ds, in some cases undetectable. G7-B and G12-YB2/0 had values closest to Rhophylac (Table 1).

**Alpha galactose.** Low levels of an additional galactose, Gal $\alpha$ 1–3Gal ( $\alpha$ -Gal), were detected by fluorescently-labeled glycans and ethyl esterification on NS0 and HH mAb-Ds and on some human B mAb-Ds by ethyl esterification only (Table 1).

Antibody	Cell line	IgG sub- class	% Galactosylation			% G0			% G1			% G2		
			Flu	Eth	GP	Flu	Eth	GP	Flu	Eth	GP	Flu	Eth	GP
IVIG		1>2>3>4	58.8	62.1	61.1	21.2	17.3	18.4	46.9	41.1	40.8	35.4	41.6	40.7
Rhophylac		1	82.3	85.6	84.4	4.6	1.7	3.3	26.2	24.2	24.4	69.2	73.4	72.2
BRAD3lab	B	3	68.6			11.4			35.0			51.0		
BRAD3clin	B	3	60.7			16.2			38.8			41.3		
mBRAD3	B	3	56.8			17.8			44.8			34.4		
BRAD5lab	B	1	78.5	73.7	77.8	0.0	2.7	0.0	42.9	41.9	39.4	57.1	52.8	58.1
BRAD5clin	B	1	64.0			12.1			41.7			43.1		
mBRAD5	B	1	53.5	59.9	66.4	14.3	5.0	6.4	45.7	55.5	45.4	30.6	32.1	43.8
G7	B	1	82.6	82.7	82.6	2.2	1.5	2.8	30.3	30.5	28.7	67.5	67.4	68.3
G12	B	1	84.2	83.4	83.8	1.1	0.8	1.3	29.5	31.7	29.4	69.4	67.5	69.1
G108	B	1		73.3	74.5		3.9	5.5		41.4	39.7		52.6	54.7
AB5	B	1		70.8	72.5		3.5	5.2		46.8	44.3		47.4	50.3
JAC10	B	1		83.8	84.9		0.0	3.0		23.8	23.8		71.8	73.0
Fog1	NS0	1	40.3	42.9	45.4	38.8	27.3	34.1	41.8	46.2	39.8	19.4	19.8	25.5
Fog1	HH	1	27.3	20.9	24.3	59.8	63.3	59.3	26.0	31.6	31.9	14.3	5.2	8.4
G7	HH	1	41.2	39.8	44.7	37.2	29.7	33.1	43.1	45.1	43.9	19.7	17.3	22.8
G12	HH	1	20.2	22.0	28.5	65.5	52.1	55.3	28.7	29.4	30.4	5.9	7.3	13.3
AD1	HH	1		38.5	37.3		32.6	40.7		37.6	43.1		19.7	15.8
MonoRho	CHO	1	26.5		32.7	54.4		46.7	38.3		38.8	7.3		13.3
rBRAD3	CHO	3	32.6			49.0			32.7			16.2		
rBRAD5	CHO	1	25.9			55.6			37.0			7.4		
Fog1	YB2/0	1	10.1	16.2	19.7	81.0	71.5	68.5	17.8	24.7	23.2	1.2	3.8	8.1
G12	YB2/0	1	54.2	56.7	61.5	20.2	16.2	17.0	51.2	54.9	42.4	28.6	29.3	40.3
R297	YB2/0	1		44.3	45.9		27.6	29.7		56.0	48.5		16.3	21.6
Fog1Δnab	YB2/0	1 null			45.7			30.6		47.4				22.0

**Table 2.** Analysis of total galactosylation and agalactosyl (G0), monogalactosyl (G1) and digalactosyl (G2) of Fc-glycans from IVIG, Rhophylac anti-D and mAb-Ds. Glycosylation analysis methods used were Flu (NP-HPLC analysis of fluorescently labelled, released N-glycans), Eth (analysis of released N-glycans by MALDI-TOF-MS after ethyl esterification) and GP (analysis of IgG Fc-glycopeptides by LC-MS).

**Culture methods affected glycosylation.** Galactosylation was higher (77%) and fucosylation lower (67%) in BRAD5lab-B derived from low cell density flask culture than in the same mAb-D produced from high cell density hollow fibre bioreactors, BRAD5clin-B and mBRAD5-B. These had 64% and 60% galactosylation and 81% and 90% fucosylation, respectively.

**Functional activity of mAb-Ds in ADCC assays was inversely related to fucosylation.** The anti-Ds varied greatly in sensitive natural killer (NK) cell FcγRIIIa-dependent ADCC activity. Four anti-Ds, namely Rhophylac, BRAD5lab-B, Fog1-YB2/0 and G12-YB2/0 exhibited sigmoidal dose-response curves and mediated high potency at relatively low concentrations (<100 ng/ml). All other mAb-Ds tested elicited less activity even at saturating concentrations. At 250 ng/ml, BRAD5lab-B had 66% and 85% greater efficacy than mBRAD5-B and rBRAD5-CHO, respectively, while Fog1-YB2/0 and G12-YB2/0 were 95–99% more efficient than their B, NS0 and HH forms in ADCC assays (Fig. 2a).

Comparison of activity with fucosylation of IgG1 anti-Ds revealed a strong negative correlation with a striking reduction in activity when fucosylation was >80% (Fig. 2b, top panels). At 25 ng/ml, which is the mean maximum physiological concentration after injection of anti-D Ig<sup>27</sup>, only four anti-Ds (Fog1-YB2/0, G12-YB2/0, BRAD5lab-B as well as Rhophylac) were active (Fig. 2b, top left panel). At 0.75–2.5 ng/ml (approximate range of detectable anti-D 10 weeks after injection<sup>27</sup>) only these three mAb-Ds were active (Fig. 2a). There was no significant relationship between ADCC activity and sialylation, galactosylation or bisecting GlcNAc of the anti-Ds at either 25 ng/ml or 750 ng/ml (Fig. 2b, lower panels). However, mBRAD5-B had equal fucosylation as G7-HH (89.5%) but higher ADCC (Fig. 2a) and more galactosylation (60% versus 42%) and bisecting GlcNAc (42% versus 2.8%), thus these sugars may have led to enhanced mBRAD5-B interactions with FcγRIIIa. The IgG3 mAb-Ds, mBRAD3-B and rBRAD3-CHO, had lower ADCC activity than equivalent forms of BRAD5 (Fig. 2a) despite lower fucosylation.

**Efficacy of mAb-Ds in human studies was affected by glycosylation.** In autologous studies, clearance of D-positive RBC was more rapid with YB2/0 mAb-Ds (Fog1<sup>28</sup> and R297<sup>29</sup>) than anti-D Ig, fast with BRAD3clin-B<sup>30</sup>, slower with BRAD3 + BRAD5 (B and CHO)<sup>31</sup> and very slow with Fog1-HH<sup>30</sup>. Clearance by Fog1-HH<sup>30</sup> and Fog1-YB2/0<sup>28</sup> was markedly dissimilar despite identical amino acid sequence, which coincided with much lower fucosylation of Fog1-YB2/0. Unexpectedly, Fog1Δnab-YB2/0 (lacking FcγR interactions<sup>32</sup>) also cleared RBC<sup>28</sup>. Fucosylation of 1:3 blends of BRAD3 + BRAD5 (B and CHO) was identical (87%) but clearance was slightly greater with mBRAD3-B + mBRAD5-B<sup>31</sup> having increased galactosylation, sialylation and bisection as compared to the CHO-cell produced variants of these antibodies (Table 4).

Using D-negative subjects, RBC clearance was slightly less effective with BRAD3clin-B and BRAD5clin-B than anti-D Ig<sup>33–35</sup>, regardless of the order of injection of anti-D and RBC - anti-D first<sup>33,34</sup> or RBC first<sup>35</sup>. However, for HH<sup>36,37</sup> and CHO<sup>38</sup> mAb-Ds injected after RBC, clearance was slow and variable although for two subjects given anti-D (G12-HH) before RBC<sup>37</sup>, clearance was rapid (Table 5).

In the following six months, immune IgG anti-D was detected 4–24 weeks after RBC injection in 0.8% (1 of 119) subjects given B mAb-Ds<sup>33–35</sup>, 62% receiving HH mAb-Ds<sup>36,37</sup>, 0% injected with MonoRho-CHO<sup>38</sup> and 0%<sup>33,36–38</sup> administered anti-D Ig (Table 5). Unexpectedly, IgM anti-D was also detected in 77% of the immunised

Antibody	Cell line	IgG sub- class	% Sialylation			% N-Acetyl	% N-Glycolyl	Linkage		% $\alpha$ 2,3		% $\alpha$ 2,6	
			Flu	Eth	GP	Eth	Eth	Flu	Eth	Flu	Eth	Flu	Eth
IVIG Rhophylac		1>2>3>4 1	19.0	23.3	19.2	23.3	0.0	$\alpha$ 2-6		0.0	0.0	19.0	23.3
			27.2	30.7	32.9	30.7	0.0	$\alpha$ 2-6	$\alpha$ 2-3,6	0.0	0.7	27.2	30.0
BRAD3lab	B	3	28.6					$\alpha$ 2-3,6		12.0		16.6	
BRAD3clin	B	3	32.4					$\alpha$ 2-3,6					
mBRAD3	B	3	27.5					$\alpha$ 2-3,6		10.1		17.4	
BRAD5lab	B	1	23.5	27.9	32.0	27.9	0.0	$\alpha$ 2-3,6	$\alpha$ 2-3,6		0.7		27.2
BRAD5clin	B	1	33.7					$\alpha$ 2-3,6		14.2		19.5	
mBRAD5	B	1	18.7	24.2	29.3	24.2	0.0	$\alpha$ 2-3,6	$\alpha$ 2-3,6	4.2	0.6	14.5	23.6
G7	B	1	35.3	35.9	38.9	35.9	0.0	$\alpha$ 2-3,6	$\alpha$ 2-3,6	10.3	0.6	25.1	35.3
G12	B	1	34.6	35.1	39.8	35.1	0.0	$\alpha$ 2-3,6	$\alpha$ 2-6	10.2	0.0	24.4	35.1
G108	B	1		32.8	34.9	32.8	0.0		$\alpha$ 2-3,6			2.3	30.5
AB5	B	1		27.9	30.5	27.9	0.0		$\alpha$ 2-3,6			1.4	26.5
JAC10	B	1		45.6	45.5	45.6	0.0		$\alpha$ 2-6			0.0	45.6
Fog1	NS0	1	5.8	7.5	9.8	0.0	7.5	$\alpha$ 2-3,6	$\alpha$ 2-3,6	0.9	1.4	4.9	6.2
Fog1	HH	1	11.7	6.6	10.7	0.0	6.6	$\alpha$ 2-3,6	$\alpha$ 2-6	2.5	0.0	9.3	6.6
G7	HH	1	22.8	29.1	25.7	0.0	29.1	$\alpha$ 2-3,6	$\alpha$ 2-3,6	2.8	1.7	20.0	27.4
G12	HH	1	10.2	15.8	18.5	0.0	15.8	$\alpha$ 2-6	$\alpha$ 2-3,6	0.0	1.7	10.2	13.9
AD1	HH	1		30.2	19.3	0.0	30.2		$\alpha$ 2-3,6			1.6	28.6
MonoRho	CHO	1	0.0		5.9			0.0		0.0		0.0	
rBRAD3	CHO	3	5.2					$\alpha$ 2-3		5.2		0.0	
rBRAD5	CHO	1	3.5					$\alpha$ 2-3		3.5		0.0	
Fog1	YB2/0	1	0.0	1.7	4.4	1.7	0.0	0.0	$\alpha$ 2-6	0.0	0.0	0.0	1.7
G12	YB2/0	1	14.3	17.0	22.3	10.4	6.7	$\alpha$ 2-3,6	$\alpha$ 2-3,6	3.7	1.1	10.6	15.9
R297	YB2/0	1		6.3	9.8	6.3	0.0		$\alpha$ 2-6			0.0	6.3
Fog1 $\Delta$ nab	YB2/0	1 null			14.6								

**Table 3.** Analysis of total sialylation, sialic acid types and linkages of Fc-glycans from IVIG, Rhophylac anti-D and mAb-Ds. Glycosylation analysis methods used were Flu (NP-HPLC analysis of fluorescently labelled, released N-glycans), Eth (analysis of released N-glycans by MALDI-TOF-MS after ethyl esterification) and GP (analysis of IgG Fc-glycopeptides by LC-MS). N-Acetyl, N-acetylneuraminic acid (NeuAc); N-Glycolyl, N-glycolylneuraminic acid (NeuGc).

subjects receiving G7-HH and G12-HH<sup>37</sup>. Assessing the efficacy of MonoRho-CHO was hindered by “rescue prophylaxis” (anti-D Ig) given to 7 subjects with slow RBC clearance<sup>38</sup>. After protracted studies of BRAD3clin-B and BRAD5clin-B which included two further RBC immunisations at 6 and 9 months, 93% (26 of 28) of the responders who developed anti-D were shown to have been protected from becoming D-immunised to the initial RBC injection by these B mAb-Ds<sup>33–35</sup> (Table 5).

## Discussion

Fc N-glycans extend from Asn297 in the N-terminal lower hinge regions of IgG into the C $\gamma$ 2 inter-domain space, forming weak interactions with the protein<sup>39–41</sup>. Both the C $\gamma$ 2 domains and the glycans are to some extent mobile and asymmetric<sup>40,41</sup>. Fc $\gamma$ RIIIa binds to both lower hinge regions<sup>42</sup>. Glycan composition may affect the N-terminal conformation or the relative orientation or mobility of C $\gamma$ 2 domains, modifying affinity for Fc $\gamma$ Rs<sup>41</sup>, although the precise mechanisms remain undefined<sup>43</sup>. Glycosylation of Fab (antigen-binding) regions of anti-D is unlikely because the integral membrane RhD proteins are surrounded by negatively charged glycoproteins in the RBC membrane glycocalyx, constricting access to the antigen<sup>44</sup>. In support of this, we recently found a strong selection against the formation of Fab-glycans during hypermutation in anti-D<sup>45</sup>.


Anti-D represents an ideal IgG for structure/function investigation and is unique because mAb-Ds from six types of cell lines could be compared with anti-D Ig synthesised by plasma cells for both *in vitro* functional activity and *in vivo* clinical data. The glycosylation of anti-Ds was heterogenous, defined by the producer cells, and influenced their biological and clinical activities.

The contribution of individual sugars to functional activity of IgG is becoming increasingly clear and may prove highly relevant for mAb-Ds.

Fucose (proximal to Asn297) was the first glycan variant found to affect the activity of human IgG1, inhibiting Fc $\gamma$ RIIIa-mediated ADCC<sup>46</sup> and phagocytosis<sup>22</sup>. It causes steric inhibition of the Fc-Fc $\gamma$ RIIIa interaction<sup>47</sup>. Afucosylated IgG has high affinity for Fc $\gamma$ RIIIa<sup>22,47</sup> displacing plasma IgG and enabling ADCC at low concentrations<sup>48</sup>. Many alloantibodies, but not all, have considerably less fucose than total IgG<sup>22–25,49</sup>. Fucosylation of anti-D in 11 prophylactic preparations was 56%–91%, while for Rhophylac this was 81%<sup>25</sup>.

The low fucosylation (<35%) of YB2/0 mAb-Ds enabled them to be highly active (effective ADCC and fast red cell clearance) but fucosylation was too high in most of the B, HH and CHO mAb-Ds for high affinity ADCC responses and accelerated red cell clearance. BRAD5lab-B was effective but when produced for clinical use fucosylation was elevated and this came with a lower efficacy. Surprisingly, most B mAb-Ds (including AB5 and JAC10) have minimal ADCC<sup>20,50</sup> perhaps because EBV immortalises immature circulating B cells synthesising highly fucosylated IgG whereas plasma cells secreting low fucosylated protective antibodies lack EBV receptors<sup>51</sup>. The high fucosylation of these B mAb-Ds is likely to explain their low ADCC.

Galactosylation of IgG has been found to be regulated by estrogens<sup>52</sup>, increased during pregnancy<sup>53</sup> and associated with pregnancy-induced remission of rheumatoid arthritis<sup>54</sup>. Agalactosylation levels of IgG have been reported to be two-fold higher in patients with rheumatoid arthritis than controls<sup>55</sup> and associated with



**Figure 2.** Functional activities of anti-D in ADCC assay. **(a)** The anti-D dependent lysis of red cells by NK cells is shown throughout the dilution range of antibody activity. Rhophylac anti-D is compared to mAb-Ds from human B cell lines, mouse cell lines, and hamster CHO and rat YB2/0 cell lines. Error bars indicate standard deviation ( $\pm$ s.d.). **(b)** Correlation between ADCC activities of anti-Ds and their glycosylation. Comparison is made of the percentage lysis of the anti-Ds (mAb-Ds and Rhophylac anti-D) shown at 25 ng/ml (left column) and 750 ng/ml (right column). The Pearson correlation coefficients for ADCC lysis and fucosylation are shown on the graphs, both were significant to  $p < 0.0001$ . There was no correlation between ADCC activity and percentage sialylation, galactosylation or bisection.

markers of inflammation<sup>56,57</sup>. Low galactosylation of anti-proteinase 3 autoantibodies correlated with inflammatory cytokines<sup>58</sup>. In our experiments, galactosylation correlated with moderately increased ADCC of BRAD5lab-B<sup>59</sup>, glycoengineered IgG1<sup>60</sup> and hypo-fucosylated anti-D<sup>61</sup>. Thus, the wide range of galactosylation ranging from Rhophylac and IgG1 B mAb-Ds (60–84% galactosylation with <15% G0) to rodent mAb-Ds (15–57% galactosylation with 18–70% G0) may impact antibody function in various ways.

Sialic acid has been described not to alter ADCC activity of IgG1<sup>60</sup>. Similarly, sialylation of anti-D had little or no effect on Fc $\gamma$ R binding<sup>61</sup> or macrophage phagocytosis of sensitised RBC<sup>62</sup>. Low sialylation of CHO and YB2/0 mAb-Ds (mean 8%) and lack of the  $\alpha$ 2,6-linkage on CHO mAb-Ds may make them liable to inflammatory responses. In addition, non-human Neu5Gc on NS0, HH and G12-YB2/0 mAb-Ds may be immunogenic<sup>63,64</sup>.

The biological relevance of bisecting GlcNAc is uncertain. Increasing it has been reported to enhance Fc $\gamma$ RIIIa-mediated ADCC, possibly by affecting fucosylation<sup>65,66</sup>, but recently, little effect has been found for monoclonal anti-D<sup>61</sup>. Bisection was very high on most B mAb-Ds.

Alpha-galactose ( $\alpha$ -Gal epitope: Gal $\alpha$ 1-3Gal $\beta$ 1-(3)4GlcNAc-R) is synthesised by all mammals except humans, apes and Old World monkeys, which produce anti-Gal<sup>67</sup>, comprising ~1% of human IgG<sup>68</sup>. Humans also have high concentrations of anti-Neu5Gc (usually higher than anti-B (blood group antibody))<sup>64</sup>. These natural

Ref-erence	Anti-D	% Fucosyl-ation	Comments on clearance	Summary of clearance	Dose-response effect	Number of subjects
30 30	BRAD3clin-B Fog1-HH	77 93	Very rapid initially then slowed Very slow, incomplete by 24 h	++++ +	Yes No	6
31 31	mBRAD3-B + mBRAD5-B rBRAD3-CHO + rBRAD5-CHO	85 (mean) 83 (mean)	Rapid initially then slowed Rapid initially then markedly slowed	+++ ++		6 6
28 28	Fog1-YB2/o Fog1Δnab-YB2/o (null)	23 46	Extremely rapid, complete by 4 h, some febrile reactions More than 50% RBC cleared by 4 h	+++++ ++++	No	5 6
29 29	R297-YB2/o Rhophylac 300	34	Extremely rapid, complete by 72 h Rapid, almost complete by 96 h	+++++ ++++	Yes Yes	6 6

**Table 4.** Clearance of autologous D-positive RBC precoated with anti-D in D-positive subjects.

Ref-erence	Anti-D	% Fucosyl-ation	Comments on clearance	Summary of clearance	Number of naïve subjects	Percentage forming anti-D before re-immunizing IgG IgM	Number of responders protected
33 33 33 34 35	BRAD3clin-B BRAD5clin-B Anti-D Ig BRAD3clin-B + BRAD5clin-B BRAD3clin-B + BRAD5clin-B	77 81 80 (mean) 80 (mean)	Mean $t_{50\%}$ = 12.7h, dose-response Mean $t_{50\%}$ = 5.9h, dose-response Mean $t_{50\%}$ = 5.0h Mean $t_{50\%}$ = 9.6h Complete by 72h in 87% (81/93) subjects	++ +++ ++++ +++ +++	10 8 8 8 93	0% 0% 0% 0% 1.7%	3 of 3 1 of 1 1 of 1 2 of 2 20 of 22
36 36	AD1-HH + AD3-HH Anti-D Ig	97	Variable, incomplete Rapid	+ / ++ ++++	5 4	60% 0%	
37 37 37 37 37	G7-HH G7-HH + G12-HH G12-HH G12-HH Anti-D Ig	90 91 93 93	Moderate Moderate Variable, incomplete Rapid Rapid	+++ + / +++ + / ++ ++++ ++++	6 3 10 2 2	67% 50% 100% 100% 60% 40% 0% 0% 0% 0%	
38 38	MonoRho-CHO Rhophylac 300	93	Slow, very variable $t_{50\%}$ = 2-203h no dose-response Rapid	+ / + / + / + / + ++++	31 15	0% 0%	

**Table 5.** Clearance of allogeneic D-positive RBC in D-negative subjects by anti-D and subsequent protection against D-immunization (prophylaxis).

antibodies may bind mAbs expressing xenogeneic  $\alpha$ -Gal and Neu5Gc epitopes, forming immune complexes and increasing uptake of target cells to antigen-presenting cells and immunogenicity. All NS0 and HH mAb-Ds expressed  $\alpha$ -Gal, as reported previously<sup>69</sup>, and Neu5Gc, also found on mAbs from some murine myelomas<sup>70</sup>. These xenogeneic epitopes may have caused HH mAb-Ds to stimulate anti-D responses, not prevent them. The findings by one laboratory of low amounts of  $\alpha$ -Gal on some human B mAb-Ds cultured in the absence of animal material are unexpected and should be taken with caution as further studies would be needed to substantiate this.

IgG3 anti-D comprises 10% of the anti-D in prophylactic preparations on average<sup>71</sup> but is relatively inefficient in ADCC compared to IgG1 anti-D as is BRAD3 (IgG3) compared to BRAD5 (IgG1)<sup>72</sup>. ADCC assays measured Fc $\gamma$ RIIIa-mediated haemolysis by NK cells although *in vivo* Fc $\gamma$ RIIIa-bearing splenic macrophages phago-cytose anti-D opsonised RBC<sup>16,17</sup>. *In vivo*, BRAD3clin-B efficiently cleared RBC<sup>30,33</sup>. *In vitro*, RBC opsonised with BRAD3lab-B had greater mean binding to splenic macrophages in cryostat sections than BRAD5lab-B opsonised RBC (58.6 and 25.8 respectively)<sup>73</sup>. Additionally, using monocyte-derived macrophages, IgG3 mAb-Ds mediated higher ADCC than IgG1 mAb-Ds (96% versus 26%)<sup>50</sup>. This difference in activity may be explained because glyco-forms of Fc $\gamma$ RIIIa vary between NK cells and monocytes<sup>74</sup> which may affect affinity to IgG subclasses and binding of differentially glycosylated IgG. Recognition of afucosylated IgG by Fc $\gamma$ RIIIa is in part mediated through carbohydrate-carbohydrate interactions involving the N162-glycan found on this receptor<sup>47</sup>.

The role of cells and Fc $\gamma$ Rs in RBC clearance is becoming clearer. *In vitro*, phagocytosis of anti-D opsonised RBC by monocytes is mediated by Fc $\gamma$ RI, with the extent of phagocytosis proportional to anti-D coverage on RBCs<sup>50</sup>. Fc $\gamma$ RI is also present on splenic red pulp macrophages and although at low expression compared to Fc $\gamma$ RIIIa, it gives a major contribution to phagocytosis<sup>75</sup>. This may be due to upregulation of surface expression of Fc $\gamma$ RI after stimulation of Fc $\gamma$ RIIIa by binding opsonised RBC or by inflammation<sup>75</sup>. Thus *in vivo*, it is likely that opsonised RBC are selected and captured by splenic macrophages through Fc $\gamma$ RIIIa binding afucosylated anti-D followed by Fc $\gamma$ RI-mediated internalisation. The spleen has the capacity to phagocytose all the fetal RBC in the majority of FMH (volumes over 20 ml fetal RBC are exceptional) without producing spherocytes or free haemoglobin. RBC with the highest opsonisation will be removed first, the rate of clearance correlating with the amount of RBC-bound anti-D<sup>14</sup> (and indirectly to D antigen levels), resulting in progressive slowing of clearance of RBC with decreasing anti-D opsonisation. Notably, antigen masking may only occur to a minor extent, as doses of anti-D cover only about 8%–20% of D antigen sites on RBC<sup>76</sup>.

Although the mechanism of anti-D prophylaxis has not been fully elucidated, clinical observations and studies performed after the introduction of anti-D Ig suggest it elicits some immunomodulatory processes. (a) Prophylactic anti-D appears to have long-term effects. HDFN was found less severe in subsequent pregnancies of women who had failures of postnatal prophylaxis compared to infants of multiparae women who had no pro-phylaxis<sup>77</sup>. Antenatal prophylaxis given only during first pregnancies, together with postnatal prophylaxis,

resulted in a 12-fold reduction in cases with D-immunisation in the second pregnancies<sup>78</sup>. These findings were recently confirmed<sup>79</sup>. It was suggested that the D-immune responses could have been modified by giving anti-D after the responses had started but before they had matured<sup>77,78</sup>. (b) Women with large fetal bleeds (FMH over 20 ml) who were given appropriate doses of anti-D Ig but had persistence of some circulating fetal RBC 6 days after delivery were subsequently found to be protected from D-immunisation, indicating that the immune response had been prevented by the sequestered RBC<sup>80</sup>. (c) IgG anti-Kell (K) injected into K- D- subjects after immunisation with K+ D+ RBC gave a 10-fold reduction in anti-D responders, compared to a control group not given anti-K. This demonstrated that after rapid clearance of RBC to the spleen, antibody-mediated immune suppression is not antigen specific but cell-specific, inhibiting antibody formation to all antigens on the RBC<sup>81</sup>. (d) Besides destruction of the RBC by anti-D Ig, another potential mechanism may be suppression of primed antigen-specific B cells by co-cross-linking B cell receptors (binding RBC antigens) and inhibitory Fc $\gamma$ RIIb (with anti-D Ig) (reviewed in<sup>76</sup>). Of note, it was reported that the YB2/0 form of a mAb-D, T125, had greater interactions with both Fc $\gamma$ RIIIa and Fc $\gamma$ RIIb than the CHO form, thus indicating that low fucosylated anti-D would be effective in this mechanism of B cell suppression<sup>82</sup> as well as in rapid RBC clearance<sup>29</sup>. (e) Other “non-specific” immunomodulatory effects of prophylactic anti-D could be caused by the anti-D or many other alloantibodies in the donor pool of immuno-globulins (similar to IVIG) using these mechanisms, such as reductions of anti-Fy<sup>a</sup> in a case report<sup>83</sup> and of anti-HLA sensitisation in a large survey<sup>84</sup>. HLA class I antigens (Bg) are expressed on most cells including RBC of some normal donors<sup>85</sup>. (f) Animal models, unfortunately, are generally unsatisfactory for understanding anti-D prophylaxis; experiments in immunocompetent mice using xenogeneic cells or glycoproteins elicit innate and/or inflammatory reactions, quite unlike allogeneic RBC and anti-D Ig in humans<sup>76</sup>.

Inflammatory responses must be avoided for RhD prophylaxis. If inflammation accompanies RBC destruction, splenic macrophages mature to DCs, present antigen to T helper (Th) cells and initiate antibody responses to allogeneic proteins<sup>18</sup>. Understandably, it must not occur with mAb-Ds or immune anti-D may be produced.

Several factors may cause inflammation. (a) Pregnant women have strong systemic immunity with mild inflammation<sup>10,11</sup> and skewing towards antibody (Th2) responses<sup>86</sup> whilst maintaining local (uterine) tolerance to the fetus<sup>13</sup>. They make robust alloantibody responses to small volumes of allogeneic blood. Consequently, most protein blood groups on RBC and alloantigens on platelets were discovered by investigating cases of HDFN and fetal and neonatal alloimmune thrombocytopenia (FNAIT). (b) Recognition of cells by innate immune receptors may induce phagocytosis accompanied by inflammatory cytokines, promoting antigen presentation; this was observed experimentally for RBC immunisation<sup>87</sup>. (c) Extracellular haemolysis liberates haemoglobin, its breakdown products induce systemic inflammatory responses (febrile reactions and cytokine storms) which can be dangerous. Haemolysis underlies the pathology of HDFN, delayed haemolytic transfusion reactions, and rare reactions of patients with idiopathic thrombocytopenia treated with anti-D<sup>88</sup>, all occurring when the phagocytic capacity of splenic macrophages is saturated and RBC are haemolyzed extracellularly.

Anti-D prophylaxis may be mediated or influenced by cytokines but data are limited. Interleukin (IL)-1Ra, an anti-inflammatory cytokine, was detected during monocyte phagocytosis of BRAD3lab-B-opsonised RBC *in vitro*<sup>89</sup>. Modest increases of tumour necrosis factor- $\alpha$  but not interferon- $\gamma$  (both pro-inflammatory) were observed briefly (at 4 h) after infusion of RBC coated with Rhophylac 300 or R297- $\gamma$ B2/o<sup>29</sup>. After antenatal prophylaxis, slight reductions of IL-1Ra (pro-inflammatory effect) were observed in plasma of 7 of 10 women while modest increases of transforming growth factor- $\beta$ 1 and prostaglandin E2 (immunoregulatory) were recorded in 7 and 5 of these women, respectively<sup>90</sup>. However, no tests to detect fetal cells (FMH) were performed so it is possible these changes in 3 of the 17 cytokines tested<sup>90</sup> were due to the immunoglobulin component, known to have immunomodulatory effects.

Great care must be taken to ensure the safety and efficacy of mAb-Ds at preventing D-immunisation before trials are performed in pregnant (and postpartum) women. First, anti-D responses are slow and low titre; half of the women immunised during pregnancy produce serologically detectable anti-D by six months post-partum and half of them in subsequent pregnancies, presumably after FMH<sup>91</sup>. Gunson *et al.* proposed this involves slow protracted phagocytosis of fetal RBC as they become effete<sup>92</sup>. Second, normal adults do not have the enhanced humoral immunity of pregnant women; anti-D developed in 50% of subjects only after 2–5 injections of D-positive RBC and rapid clearance of these RBC often occurred before anti-D was detected serologically<sup>93</sup>. Therefore, in the early clinical trials of anti-D, subjects were re-immunised with D-positive RBC several times between 6 and 12 months<sup>33–35,94</sup>. Primary and secondary anti-D responses were detectable 2–4 months or 1–4 weeks after re-immunisation, respectively. This determines which subjects were (a) D-immunised by the first injection of RBC (failure of prophylaxis), (b) D-immunised after RBC challenge (protection by prophylaxis) and (c) non-responders who never make anti-D (non-informative).

Thus both appropriate clinical testing and anti-D glycosylation are required for success with prophylactic mAb-Ds. The previously published clinical trial data of the anti-Ds in this study can be summarised. *Anti-D Ig*: high ADCC, very rapid RBC clearance, prevented D-immunisation. *B mAb-Ds*: (BRAD3, BRAD5) medium ADCC, fast clearance, prevented D-immunisation in 93% subjects, insufficient dose. *HH mAb-Ds*: (Fog1, AD1, G7, G12) low ADCC, variable and slow clearance, stimulated D-immunisation. *CHO mAb-Ds*: (BRAD3, BRAD5, MonoRho) low ADCC, slow and variable clearance, MonoRho may have prevented D-immunisation but this is not proven. *YB2/0 mAb-Ds*: (Fog1, Fog1 $\Delta$ nab, R297) very high ADCC, extremely rapid clearance.

Unfortunately, after much work over three decades, none of the mAb-Ds in this study and also Sym001-CHO (Rozrolimupab)<sup>95</sup> are still in clinical development for prophylaxis against HDFN although the results of prevention of D-immunisation in a phase II/III trial of Roledumab- $\gamma$ B2/o (R297 with low fucosyl transferase)<sup>96,97</sup> are awaited with great interest.

Prophylaxis against FNAIT has been proposed and anti-HPA-1a immunoglobulin is being prepared from women immunised by pregnancy for trials<sup>98</sup>. Because anti-HPA-1a is rarely produced after

platelet transfusion<sup>99,100</sup>, donors could not be immunised for anti-HPA-1a immunoglobulin, thus monoclonal anti-HPA-1a would be needed for prophylaxis<sup>101</sup>.

This study has shown that the biological activity of mAb-Ds is defined by their producer cell lines. Our results indicate that glycosylation is likely a key determinant of clinical effectiveness. The optimal glycosylation for prophylactic mAb-Ds (and monoclonal anti-HPA-1a) might be different from that of highly cytotoxic monoclonal antibodies for cancer therapy<sup>102</sup>, because haemolysis and inflammation must be avoided. Therefore, to copy and replace anti-D Ig and to prevent possible adverse effects, galactosylation should be over 60% with G2 > G1 > G0 to enhance functional activity. However, lower fucosylation (under 60%) than in most prophylactic anti-Ds<sup>25</sup> would promote efficient Fc $\gamma$ RIIIa interactions and rapid RBC clearance at low mAb-D concentrations. From the available data, these limits may be the best current estimate for reliable, potent mAb-Ds. Of note, abundant supplies of safe, effective and affordable mAb-D are urgently needed to reduce the global burden of HDFN.

## Materials and Methods

**IgG antibodies.** mAb-Ds were produced from human EBV-transformed B-lymphoblastoid cell lines (B), mouse myeloma cell lines (NS0 or mouse/human heterohybridomas (HH) formed by fusion of B and P3X63Ag8.653 cell lines), Chinese hamster ovary (CHO) cell lines and rat myeloma YB2/0 or rat/human heterohybridoma cell lines. All mAb-Ds were IgG1 except BRAD3 (IgG3). The following individuals submitted antibodies for glycosylation analysis: Sylvia Miescher, (Rhophylac 300 (300  $\mu$ g, 1500 IU, 2 ml) anti-D Ig (Quality Control Grade, Lot 02905-00092) and MonoRho-CHO); Rosey Mushens, (BRAD3lab-B, BRAD5lab-B, JAC10-B, AB5-B, Fog1-HH); Joan Dalton, (BRAD3clin-B, mBRAD3-B, rBRAD3-CHO, BRAD5clin-B, mBRAD5-B, rBRAD5-CHO); Natalia Olovnikova (G7-B, G7-HH, G12-B, G12-HH, G12-YB2/o (rat/human), G108-B); Christof de Romeuf, (AD1-HH, R297-YB2/o); Kathryn Armour (Fog1-ns0, Fog1-YB2/o and Fog1 $\Delta$ nab-YB2/o<sup>32</sup>). BRAD3lab-B and BRAD5lab-B were prepared from low cell density flask cultures for experimental use and BRAD3clin-B and BRAD5clin-B were produced for clinical testing<sup>33</sup> in high cell density hollow fibre bioreactors; mBRAD3-B, mBRAD5-B, rBRAD3-CHO and rBRAD5-CHO were subsequently also produced from hollow fibre bioreactors<sup>31</sup>. IVIG (Hepatect CP 50 IU/ml) was kindly provided by P. Griffiths from Biotest (UK) Ltd, Birmingham, UK.

**Purification and quantification of IgG anti-D.** Anti-D was affinity purified from Rhophylac 300 anti-D Ig<sup>44</sup>. IgGs from this RBC eluate and from culture supernatants of mAb-Ds were purified using Protein G and IgG concentrations determined by ELISA. Only IgG1 was detected in anti-D purified from Rhophylac 300 (at 10  $\mu$ g/ml) by haemagglutination with anti-IgG subclass mAbs<sup>44</sup>. The anti-D fraction termed Rhophylac was used in this study.

### Glycosylation analysis 1: N-glycan analysis in NIBRT GlycoScience Group, Dublin (Flu).

Antibodies were reduced, alkylated and N-glycans were released from IgG heavy chain from SDS-PAGE gel bands by digestion with N-glycosidase F (PNGase F, Prozyme, San Leandro, CA) as described by Royle *et al.*<sup>103</sup>. Briefly, gels were washed and N-glycans were released by PNGase F. Released N-glycans were fluorescently labelled with 2-aminobenzamide (2-AB) by reductive amination using a LudgerTagTM 2-AB labelling kit (Ludger Ltd., Abingdon, UK) and excess of 2-AB was removed by paper chromatography<sup>103</sup>.

Labelled glycans were analysed by 3 hours normal phase high-performance liquid chromatography (NP-HPLC) using a TSK-Gel Amide-80 4.6  $\times$  250 mm column (Anachem, Luton, UK) on a 2695 Alliance separations module (Waters, Milford, MA) equipped with a Waters temperature control module and a Waters 2475 fluorescence detector. Solvent A was 50 mM formic acid adjusted to pH 4.4 with ammonia solution. Solvent B was acetonitrile. Gradient conditions were a linear gradient of 20–58% A, over 152 min at a flow rate of 0.4 mL/min. Samples were injected in 80% acetonitrile<sup>103</sup>. Fluorescence was measured at 420 nm with excitation at 330 nm. The system was calibrated using an external standard of hydrolysed and 2AB-labeled glucose oligomers to create a dextran ladder, as described previously<sup>103</sup>. NP-HPLC chromatograms generated from the samples are in Supplementary Fig. S1.

For exoglycosidase digestion of 2-AB labelled N-glycans, enzymes were supplied by Prozyme. The 2AB-labelled glycans were digested in a volume of 10  $\mu$ L for 18 h at 37 °C in 50 mM sodium acetate buffer, pH 5.5 (except in the case of jack bean  $\alpha$ -mannosidase (JBM) where the buffer was 100 mM sodium acetate, 2 mM Zn<sup>2+</sup>, pH 5.0), using arrays of the following enzymes: *Arthrobacter ureafaciens* sialidase (ABS, EC 3.2.1.18), 0.5 U/mL; *Streptococcus pneumoniae* sialidase (NAN1, EC 3.2.1.18), 1 U/mL; coffee bean alpha galactosidase (CBG, EC 3.2.1.22), 25 U/mL; bovine testes  $\beta$ -galactosidase (BTG, EC 3.2.1.23), 1 U/mL; bovine kidney alpha-fucosidase (BKF, EC 3.2.1.51), 1 U/mL and JBM (EC 3.2.1.24), 60 U/mL. After incubation, enzymes were removed by filtration through 10 kDa protein-binding EZ filters (Millipore Corporation)<sup>103</sup>. N-glycans were assigned using exoglycosidase digestions (Supplementary Table S2) and Glycobase and features outlined in Tables 1–3 were calculated based on these assignments (Supplementary Table S2).

### Glycosylation analysis 2: N-glycan analysis at Leiden University Medical Center. IgG Total N-glycosylation analysis (Eth).

After protein denaturation, N-glycans were released with 1 mU recombinant peptide-N-glycosidase F (PNGase F; Roche Diagnostics, Mannheim, Germany) at 37 °C overnight as described previously<sup>104,105</sup>. The selective ethyl-esterification of 2,6-linked sialic acids and lactonization of 2,3-linked sialic acid was performed on the released N-glycans<sup>106</sup>, followed by glycan purification by HILIC-SPE using cotton as stationary phase<sup>107</sup> and glycan elution with 10  $\mu$ L of water. For MALDI-TOF-MS analysis, samples were spotted on an AnchorChip MALDI target (Bruker Daltonics, Bremen, Germany) together with sodiated (1 mM NaOH) Super-DHB (Sigma-Aldrich) matrix. All analyses were performed on an UltraFlex extreme MALDI-TOF/TOF-MS equipped with a Smartbeam II laser (FlexControl 3.4 Build 119, Bruker Daltonics). The MS was operated in reflectron positive (RP) ion mode, calibrated on the known masses of a peptide calibration standard (Bruker Daltonics). For sample measurements 10000 laser shots were accumulated at a laser frequency of 1000 Hz, using a complete sample random walk with 200 shots per raster spot. Tandem mass spectrometry (MALDI-TOF/TOF-MS/MS)

was performed on mostly sialylated variants of IgG glycans via laser-induced dissociation, and compositions as well as structural features of N-glycans were confirmed on the basis of the observed fragment ions (not shown).

Spectra were exported as text and subjected to recalibration and data extraction using an in-house developed Python script. Glycan peaks were detected and extracted using a signal/noise cut-off of 3. Total glycan intensity per spectrum was normalised to 100%, and derived traits were calculated based on the compositional features (Supplementary Tables S3 and S4) (hexose = H; N-acetylhexosamine = N; fucose = F;  $\alpha$ 2,6-linked N-acetylneuraminic acid = E;  $\alpha$ 2,3-linked N-acetylneuraminic acid = L;  $\alpha$ 2,6-linked N-glycolylneuraminic acid = Ge;  $\alpha$ 2,3-linked N-glycolylneuraminic acid = Gl).

**Glycosylation analysis 3: IgG Fc glycopeptide analysis (N-glycosylation) at Leiden University Medical Center (GP).** IgG was enzymatically digested with trypsin and analysed by reverse phase-nanoLC-MS. Electrospray ionisation was achieved with a CaptiveSpray nanoBooster (Bruker Daltonics) using acetonitrile-enriched nitrogen gas to enhance sensitivity. Glycopeptides were detected using a quadrupole-time-of-flight (TOF) mass spectrometer (MS) (maXis impact HD ultra-high resolution QTOF; Bruker Daltonics)<sup>108</sup>. Double and triple charged tryptic Fc glycopeptide signals were integrated and normalised to the subclass-specific total glycopeptide intensity. Quality of mass spectra was evaluated based on intensities of total IgG1 glycoforms. Glycosylation traits were calculated as detailed in Supplementary Table S3.

**Analysis of mAb-D glycosylation in small scale earlier studies.** Methods used for other studies reported in Supplementary Table S1 were MALDI-TOF-MS analysis of IgG1 Fc-glycopeptides<sup>25</sup>, analysis by HVE-AEC, gel filtration chromatography and Concanavalin A binding of oligosaccharides released by hydrazinolysis<sup>109</sup>, quantitation of % G0 by binding of GlcNAc-specific mAb GN7<sup>59</sup>, chromatographic separation of fluorescently labelled neutral oligosaccharides<sup>49</sup>, enzymatically released glycans analysed by HPCE-LIF<sup>82</sup> and FAB-MS and MALDI-MS of permethylated N-glycans (Carbohydrate structure of rBRAD-3 and rBRAD-5; Joan Dalton, BioProducts Laboratory, UK, email, September 26, 2007; permission to publish subsequently given).

**ADCC assay.** Peripheral blood mononuclear cells (PBMC) depleted of adherent monocytes were incubated in triplicate for 16 h at 37 °C with papainized <sup>51</sup>Cr-labelled group OR<sub>1</sub>R<sub>2</sub> RBC (15:1 ratio) and anti-D in RPMI1640 containing 3% AB serum (to block Fc $\gamma$ RI on residual monocytes)<sup>50</sup> and 7% fetal calf serum; after centrifugation, radioactivity was determined in aliquots of supernatant<sup>72</sup>. The percent specific lysis (% haemo-lysis) was calculated as: % specific lysis = 100  $\times$  (experimental release – spontaneous release)/(maximum release – spontaneous release). To confirm Fc $\gamma$ R utilisation, lysis by IgG1 anti-D was blocked by anti-Fc $\gamma$ RIII (3G8) but not by anti-Fc $\gamma$ RII (IV.3)<sup>50</sup>.

**Analysis of data from previous clinical trials of RBC clearance and prevention of D-immunization.** The efficacy of prophylactic anti-D Ig depends on removal of fetal RBC from the circulation by 72 hours<sup>110</sup>. Clinically, tests for FMH are performed to determine whether fetal D-positive RBC have been cleared by this time<sup>111</sup>. For initial clinical trials, pre-menopausal women are not enrolled because they might become D-immunised which could lead to HDFN in subsequent pregnancies. Early studies showed that if anti-D prevented D-immunisation in men, it would be suitable for prophylaxis in women. Using healthy male volunteers, eight mAb-Ds had been tested in four autologous RBC clearance studies and seven mAb-Ds in five allogeneic RBC clearance studies. All the trial protocols varied; details of methods, ethics approval and informed consent are given in the original papers cited in Tables 4 and 5. Autologous RBC clearance measured the extent of radioactivity remaining in blood of D-positive subjects after injection of their *ex vivo* <sup>51</sup>Cr labelled RBC coated with anti-D. Study periods were between 1 h and 6 days after injection. Allogeneic studies measured clearance of D-positive RBC (labelled with <sup>51</sup>Cr or detected by flow cytometry) injected into D-negative recipients before (simulating postnatal prophylaxis) or after (equivalent to antenatal prophylaxis) anti-D administration, with blood samples taken up to 7 days. To assess whether mAb-D could prevent D-immunisation, these subjects were then tested regularly (every 2 or 4 weeks) for 6 months to detect anti-D responses (indicating failure of prophylaxis). In studies of B mAb-Ds, subjects were then re-immunised with D-positive RBC at 6 and 9 months and tested regularly up to a year to determine which were responders to these unprotected immunisations who had been prevented from making anti-D after the first RBC injection by mAb-Ds.

### Data availability

All data generated or analysed during this study are included in this published article and its Supplementary Information files. Not all mAb-Ds (antibodies or cell lines) may be available due to being produced many years ago in laboratories that have since ceased working on them or closed down.

Received: 3 January 2019; Accepted: 17 December 2019;

Published online: 30 January 2020

### References

1. Bowman, J. M. RhD haemolytic disease of the newborn. *N. Engl. J. Med.* **334**, 1775–1757 (1998).
2. Zipursky, A., Bhutani, V. K. & Odame, I. Rhesus disease: a global prevention strategy. *Lancet Child. Adolesc. Health.* **2**, 536–542 (2018).
3. Bhutani, V. K. *et al.* Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. *Pediatr. Res.* **74**((Suppl 1), 86–100 (2013).
4. Olovnikova, N. I. Is an expression system for producing therapeutic antibodies with immunosuppressive properties found at last? Comment to letter by Dr. Quagliarioli. *Biochemistry (Mosc.)* **78**, 1374–1375 (2013).
5. Dajak, S., Roje, D., Hašpl, Ž. H. & Maglič, P. E. The importance of antenatal prevention of RhD immunisation in the first pregnancy. *Blood Transfus.* **12**, 410–415 (2014).
6. Tovey, L. A. D. ABC of Transfusion. Haemolytic disease of the newborn and its prevention. *Br. Med. J.* **300**, 313–316 (1990).

7. Woodrow, J. C. & Finn, R. Transplacental haemorrhage. *Br. J. Haematol.* **12**(6720), 297–309 (1966).
8. Bowman, J. M., Pollock, J. M. & Penston, L. E. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. *Vox Sang.* **51**, 117–121 (1986).
9. Zipursky, A., Hull, A., White, F. D. & Israels, L. G. Foetal erythrocytes in the maternal circulation. *Lancet* **1**, 451–452 (1959).
10. Germain, S. J., Sacks, G. P., Sooranna, S. R., Sargent, I. L. & Redman, C. W. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. *J. Immunol.* **178**, 5949–5956 (2007).
11. Göhner, C., Plösch, T. & Faas, M. M. Immune-modulatory effects of syncytiotrophoblast extracellular vesicles in pregnancy and preeclampsia. *Placenta* **60**, S41–S51 (2017).
12. Schumacher, A., Costa, S.-D. & Zenclussen, A. C. Endocrine factors modulating immune responses in pregnancy. *Front. Immunol.* **5**, 196 (2014).
13. Kumpel, B. M. & Manoussaka, M. S. Placental immunology and maternal alloimmune responses. *Vox Sang.* **102**, 2–12 (2012).
14. Mollison, P. L., Crome, P., Hughes-Jones, N. C. & Rochna, E. Rate of removal from the circulation of red cells sensitized with different amounts of antibody. *Br. J. Haematol.* **11**, 461–470 (1965).
15. Hughes-Jones, N. C., Mollison, P. L. & Veall, N. Removal of incompatible red cells by the spleen. *Br. J. Haematol.* **3**, 125–133 (1957).
16. Engelfriet, C. P. The immune destruction of red cells. *Transfus. Med.* **2**, 1–6 (1992).
17. Armour, K. L. *et al.* Clearance of human IgG1-sensitized red blood cells *in vivo* in humans relates to the *in vitro* properties of antibodies from alternative cell lines. *PLoS One* **9**, e109463 (2014).
18. Kumpel, B. M. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. *Transfusion* **46**, 1652–1656 (2006).
19. Kumpel, B. M. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. *Vox Sang.* **93**, 99–111 (2007).
20. Kumpel, B. M. *et al.* Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis. *Eur. J. Immunol.* **19**, 2283–2288 (1989).
21. Takahashi, N. *et al.* Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G. *Biochemistry* **26**, 1137–1144 (1987).
22. Kapur, R. *et al.* A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. *Blood* **123**, 471–480 (2014).
23. Kapur, R. *et al.* Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. *Br. J. Haematol.* **166**, 936–945 (2014).
24. Sonneveld, M. E. *et al.* Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn. *Br. J. Haematol.* **176**, 651–660 (2017).
25. Kapur, R. *et al.* Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. *Transfusion* **55**, 553–562 (2015).
26. Fokkink, W. J. *et al.* Comparison of Fc N-glycosylation of pharmaceutical products of intravenous immunoglobulin G. *PLoS One* **10**, e0139828, <https://doi.org/10.1371/journal.pone0139828> (2015).
27. Tibblad, E., Wikman, A., Rane, A., Jansson, Y. & Westgren, M. Pharmacokinetics of 250 µg anti-D IgG in the third trimester of pregnancy: an observational study. *Acta Obstet. Gynecol. Scand.* **91**, 587–592 (2012).
28. Armour, K. L. *et al.* Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. *Blood* **107**, 2619–2626 (2006).
29. Béliard, R. *et al.* A human anti-D monoclonal antibody selected for enhanced Fc $\gamma$ RIII engagement clears RhD<sup>+</sup> autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. *Br. J. Haematol.* **141**, 109–119 (2008).
30. Thomson, A. *et al.* Clearance of Rh D-positive red cells with monoclonal anti-D. *Lancet* **336**, 1147–1150 (1990).
31. Chapman, G. E. *et al.* The clearance kinetics of autologous RhD-positive erythrocytes coated *ex vivo* with novel recombinant and monoclonal anti-D antibodies. *Clin. Exp. Immunol.* **150**, 30–41 (2007).
32. Armour, K. L., Clark, M. R., Hadley, A. G. & Williamson, L. M. Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities. *Eur. J. Immunol.* **29**, 2613–2624 (1999).
33. Kumpel, B. M. *et al.* Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D<sup>+</sup> red blood cells and suppression of Rh D immunization in Rh D<sup>-</sup> volunteers. *Blood* **86**, 1701–1709 (1995).
34. Smith, N. A. *et al.* A multi-centre trial of monoclonal anti-D in the prevention of Rh-immunisation of RhD- male volunteers by RhD<sup>+</sup> red cells. *Transfus. Med.* **10**(Suppl. 1), 8 (2000).
35. Kumpel, B. M. *In vivo* studies of monoclonal anti-D and the mechanism of immune suppression. *Transfus. Clin. Biol.* **9**, 9–14 (2002).
36. Béliard, R. Monoclonal antibodies to prevent alloimmunization: lessons from clinical trials. *Transfus. Clin. Biol.* **13**, 58–64 (2006).
37. Olovnikova, N. I. *et al.* Rapid clearance of Rhesus-positive erythrocytes with monoclonal anti-Rhesus antibodies is insufficient for effective prevention of Rhesus sensitization. *Bull. Exp. Biol. Med.* **129**, 77–81 (2000).
38. Miescher, S. *et al.* A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the Fc $\gamma$ RIIA and Fc $\gamma$ RIIIA genes. *Blood* **103**, 4028–4035 (2004).
39. Lund, J., Takahashi, N., Pound, J. D., Goodall, M. & Jefferis, R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharides. *J. Immunol.* **157**, 4963–4969 (1996).
40. Wormald, M. R. *et al.* Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. *Biochemistry* **36**, 1370–1380 (1997).
41. Krapp, S., Mimura, Y., Jefferis, R., Huber, R. & Sonderrmann, P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. *J. Mol. Biol.* **325**, 979–989 (2003).
42. Sonderrmann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. *Nature* **406**, 267–273 (2000).
43. Hansom, Q. M. & Barb, A. W. A perspective on the structure and receptor-binding properties of immunoglobulin G Fc. *Biochemistry* **54**, 2931–2942 (2015).
44. Kumpel, B. M. *et al.* Antigen topography is critical for interaction of IgG2 anti-red-cell antibodies with Fc $\gamma$  receptors. *Br. J. Haematol.* **94**, 175–183 (1996).
45. van de Bovenkamp, F. S. *et al.* Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. *Proc. Natl. Acad. Sci. USA* **115**, 1901–1906 (2018).
46. Shields, R. L. *et al.* Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc $\gamma$ RIII and antibody-dependent cellular toxicity. *J. Biol. Chem.* **277**, 26733–26740 (2002).
47. Ferrara, C. *et al.* Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc $\gamma$ RIII and antibodies lacking core fucose. *Proc. Natl. Acad. Sci. USA* **108**, 12669–12674 (2011).
48. Iida, S. *et al.* Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to Fc gammaRIIIa. *Clin. Cancer Res.* **12**, 2879–2887 (2006).
49. Olovnikova, N. I., Ershler, M. A., Grigorieva, O. V., Petrov, A. V. & Miterov, G. Y. Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties. *Biochemistry (Mosc.)* **77**, 925–933 (2012).
50. Kumpel, B. M. *et al.* Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report. *Transfus. Clin. Biol.* **9**, 45–53 (2002).

51. Olovnikova, N. Anti-RhD-Mediated Immunosuppression: Can Monoclonal Antibodies Imitate the Action of Polyclonal Antibodies? (eds. Kapur, S. & Portela, M.B.) *Immunosuppression - Role in Health and Diseases*. 77–106, <https://doi.org/10.5772/28744>, <https://www.intechopen.com/books/immunosuppression-role-in-health-and-diseases/anti-rhd-mediated-immunosuppression-can-monoclonal-antibodies-imitate-the-action-of-polyclonal-antib> (InTech: Rijeka, Croatia, 2012).
52. Ercan, A. *et al.* Estrogens regulate glycosylation of IgG in women and men. *JCI Insight* **2**, e89703, <https://doi.org/10.1172/jci.insight89703> (2017).
53. Rook, G. A. *et al.* Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. *J. Autoimmun.* **4**, 779–794 (1991).
54. Bondt, A. *et al.* Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. *J. Proteome Res.* **12**, 4522–4531 (2013).
55. Parekh, R. B. *et al.* Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. *Nature* **316**, 452–457 (1985).
56. Troelsen, L. N. *et al.* IgG glycosylation changes and MBL2 polymorphisms: association with markers of systemic inflammation and joint destruction in rheumatoid arthritis. *J. Rheumatol.* **39**, 463–469 (2012).
57. Collins, E. S. *et al.* Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. *Rheumatology (Oxford)* **52**, 1572–1582 (2013).
58. Wuhrer, M. *et al.* Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation and sialylation. *J. Proteome Res.* **14**, 1657–1665 (2015).
59. Kumpel, B. M., Wang, Y., Griffiths, H. L., Hadley, A. G. & Rook, G. A. The biological activity of human monoclonal IgG anti-D is reduced by  $\beta$ -galactosidase treatment. *Hum. Antibodies Hybridomas* **6**, 82–88 (1995).
60. Thomann, M. *et al.* *In vitro* glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. *PLoS One* **10**, e0134949, <https://doi.org/10.1371/journal.pone0134949> (2015).
61. Dekkers, G. *et al.* Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. *Front. Immunol.* **8**, 877, <https://doi.org/10.3389/fimmu00877> (2017).
62. Nagelkerke, S. Q. *et al.* Inhibition of Fc $\gamma$ R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc $\gamma$ RIIb in human macrophages. *Blood* **124**, 3709–3718 (2014).
63. Raju, T. S., Briggs, J. B., Borge, S. M. & Jones, A. J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. *Glycobiology* **10**, 477–486 (2000).
64. Padler-Karavani, V. *et al.* Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. *Glycobiology* **18**, 818–830 (2008).
65. Umaña, P., Jean-Mairet, J., Moudry, R., Amstutz, H. & Bailey, J. E. Engineered glycoforms of an antineuroblastoma IgG1 with optimised antibody-dependent cellular cytotoxic activity. *Nat. Biotechnol.* **17**, 176–180 (1999).
66. Davies, J. *et al.* Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. *Biotechnol. Bioeng.* **74**, 288–294 (2001).
67. Galili, U. The  $\alpha$ -gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. *Immunol. Cell Biol.* **83**, 674–686 (2005).
68. Galili, U., Anaraki, F., Thall, A., Hill-Black, C. & Radic, M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. *Blood* **82**, 2485–2493 (1993).
69. Montaña, R. F. & Romano, E. L. Human monoclonal anti-Rh antibodies produced by human-mouse heterohybridomas express the Gal  $\alpha$ 1-3 Gal epitope. *Hum. Antibodies Hybridomas* **5**, 152–156 (1994).
70. Ghaderi, D., Taylor, R., Padler-Karavani, V., Diaz, S. & Varki, A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. *Nat. Biotechnol.* **28**, 863–867 (2010).
71. Gorick, B. D. & Hughes-Jones, N. C. Relative functional binding activity of IgG1 and IgG3 anti-D in IgG preparations. *Vox Sang.* **61**, 251–254 (1991).
72. Kumpel, B. M. *In vitro* functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D. *Vox Sang.* **72**, 45–51 (1997).
73. Kumpel, B. M. & Davenport, R. D. Comparison of two Fc $\gamma$ RIII-mediated assays of anti-D functional activity, using spleen and K cells. *Transfus. Med.* **6**(Suppl.2), 20 (1996).
74. Edberg, J. C. & Kimberly, R. P. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. *J. Immunol.* **159**, 3849–3857 (1997).
75. Nagelkerke, S. Q. *et al.* Red pulp macrophages in the human spleen are a distinct cell population with a unique expression of Fc $\gamma$  receptors. *Blood Adv.* **2**, 941–953 (2018).
76. Kumpel, B. M. & Elson, C. J. Mechanism of anti-D-mediated immune suppression – a paradox awaiting resolution? *Trends Immunol.* **22**, 26–31 (2001).
77. Tovey, L. A. & Robinson, A. E. Reduced severity of Rh-haemolytic disease after anti-D immunoglobulin. *Brit. Med. J.* **4**, 320–322 (1975).
78. Thornton, J. G. *et al.* Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. *Brit. Med. J.* **298**, 1671–1673 (1989).
79. Koelewijn, J. M., de Haas, M., Vrijkotte, T. G., Bonsel, G. J. & van der Schoot, C. E. One single dose of 200 ug of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. *Transfusion* **48**, 1721–1729 (2008).
80. Lubenko, A. *et al.* Monitoring the clearance of fetal RhD-positive red cells in FMH following RhD immunoglobulin administration. *Transfus. Med.* **9**, 331–335 (1999).
81. Woodrow, J. C. *et al.* Mechanism of Rh prophylaxis: an experimental study on specificity of immunosuppression. *Brit. Med. J.* **2**, 57–59 (1975).
82. Siberil, S. *et al.* Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc $\gamma$ R functions. *Clin. Immunol.* **118**, 170–179 (2006).
83. Branch, D. R., Scofield, T. L., Moulds, J. J. & Swanson, J. L. Unexpected suppression of anti-Fya and prevention of hemolytic disease of the fetus and newborn after administration of Rh immune globulin. *Transfusion* **51**, 816–819 (2010).
84. Kaufman, R. M., Schlumpf, K. S., Wright, D. J. & Triulzi, D. J. Does Rh immune globulin suppress HLA sensitization in pregnancy? *Transfusion* **53**, 2069–2077 (2013).
85. Giles, C. M., Botto, M. & King, M. J. A study of HLA (Bg) on red cells and platelets by immunoblotting with monoclonal antibodies. *Transfusion* **30**, 126–132 (1990).
86. Wegmann, T. G., Lin, H., Guilbert, L. & Mossman, T. R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? *Immunol. Today* **14**, 353–356 (1993).
87. Hendrickson, J. E. *et al.* Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. *Transfusion* **46**, 1526–1536 (2006).
88. Gaines, A. R. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0) (D) immune globulin intravenous administration for immune thrombocytopenic purpura. *Blood* **106**, 1532–1537 (2005).
89. Coopamah, M. D., Freedman, J. & Semple, J. W. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. *Blood* **102**, 2862–2867 (2003).

90. Branch, D. R., Shabani, F., Lund, N. & Denomme, G. A. Antenatal administration of Rh immune globulin causes significant increases in the immunomodulatory cytokines Transforming Growth Factor beta1 and prostaglandin E2. *Transfusion* **46**, 1316–1322 (2006).
91. Clarke, C. A. *et al.* Prevention of Rh-haemolytic disease: results of the clinical trial (1966). A combined study from centres in England and Baltimore. *Brit. Med. J.* **2**, 907–914 (1966).
92. Gunson, H. H., Stratton, F., Cooper, D. G. & Rawlinson, V. I. Primary immunization of Rh-negative volunteers. *Br. Med. J.* **1**, 593–595 (1970).
93. Woodrow, J. C., Finn, R. & Krevans, J. R. Rapid clearance of Rh positive blood during experimental Rh immunization. *Vox Sang.* **17**, 349–361 (1969).
94. Pollack, W. *et al.* Studies on Rh prophylaxis. I. Relationship between doses of anti-Rh and size of antigenic stimulus. *Transfusion* **11**, 333–339 (1971).
95. Stasi, R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. *Curr. Opin. Mol. Ther.* **12**, 734–740 (2010).
96. Yver, A. *et al.* Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimised Fc for improved engagement of FC $\gamma$ RIII, in healthy volunteers. *Vox Sang.* **103**, 213–222 (2012).
97. Laboratoire français de Fractionnement et de Biotechnologies. Pharmacokinetics and safety of Roledumab, in RhD-negative pregnant women carrying an RhD-positive foetus. Posted 11<sup>th</sup> November 2014, study completed 13<sup>th</sup> September 2017, <https://clinicaltrials.gov/ct2/show/NCT02287896>. Accessed November 10<sup>th</sup>, (2019).
98. Weng, Y. J. *et al.* Anti-human platelet antigen-1a immunoglobulin G preparation intended to prevent fetal and neonatal alloimmune thrombocytopenia. *PLoS One* **11**, e0162973, <https://doi.org/10.1371/journal.pone0162973> (2016).
99. Kiefel, V., König, C., Kroll, H. & Santoso, S. Platelet alloantibodies in transfused patients. *Transfusion* **41**, 766–770 (2001).
100. Engelfriet, C. P. & Reesink, H. W. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. *Vox Sang.* **84**, 73–88 (2003).
101. Kumpel, B. M. Would it be possible to prevent HPA-1a alloimmunization to reduce the incidence of fetal and neonatal alloimmune thrombocytopenia? *Transfusion* **52**, 1393–1397 (2012).
102. van Berkel, P. H. *et al.* N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. *Biotechnol. Prog.* **25**, 244–251 (2009).
103. Royle, L., Radcliffe, C. M., Dwek, R. A. & Rudd, P. M. Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. *Methods Mol. Biol.* **347**, 125–143 (2006).
104. Ruhaak, L. R. *et al.* Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins. *Anal. Chem.* **80**, 6119–6126 (2008).
105. Pucić, M. *et al.* High throughput isolation and glycosylation analysis of IgG variability and heritability of the IgG glycome in three isolated human populations. *Mol. Cell. Proteomics*. **10**, M111.010090, <https://doi.org/10.1074/mcpM111.010090> (2011).
106. Reiding, K. R., Blank, D., Kuijper, D. M., Deelder, A. M. & Wührer, M. High throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification. *Anal. Chem.* **86**, 5784–5793 (2014).
107. Selman, M. H., Hemayatkar, M., Deelder, A. M. & Wührer, M. Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. *Anal. Chem.* **83**, 2492–2499 (2011).
108. Selman, M. H. *et al.* Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. *J. Proteomics* **75**, 1318–1329 (2012).
109. Kumpel, B. M., Rademacher, T. W., Rook, G. A., Williams, P. J. & Wilson, I. B. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. *Hum. Antibodies Hybridomas* **5**, 143–151 (1994).
110. Qureshi, H. *et al.* BCSH guidelines for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. *Transfus. Med.* **24**, 8–20 (2014).
111. Kumpel, B. *et al.* Accurate quantitation of D+ fetomaternal haemorrhage by flow cytometry using a novel reagent to eliminate granulocytes from analysis. *Transfusion*. **54**, 1305–1316 (2014).

## Acknowledgements

R.S. would like to acknowledge funding from Science Foundation Ireland Starting Investigator Research Grant (SFI SIRG) (13/SIRG/2164) and funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement nu260600 (“GlycoHIT”). We are grateful to Joan Dalton (BioProducts Laboratory, Elstree, UK), Rosey Mushens (International Blood Group Reference Laboratory, Bristol, UK), Sylvia Miescher (CLB-Behring, Berne, Switzerland) and Christof de Romeuf (LFB, Lille, France) who submitted mAb-Ds.

## Author contributions

B.M.K. conceived the study, gathered the IgG samples, made the tables and analysed the data. B.M.K. and N.I.O. performed ADCC assays. K.L.A., B.M.K. and R.K. made the figures. A.H.E., C.A.K. and J.L.A. performed glycan experiments. R.S., P.M.R. and M.W. did the glycosylation analysis. P.M.R., M.W. and G.V. designed the glycosylation studies. B.M.K. wrote the paper which was critically revised and approved by all the authors.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41598-019-57393-9>.

**Correspondence** and requests for materials should be addressed to B.M.K. or G.V.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020